Ribavirin의 소아만성 B형 간염에 대한 치료효과

Therapeutic Trial of Ribavirin on Chronic Hepatitis B in Children

소아만성B형간염 환아 24명에게 항virus제인 ribavirin을 15mg/kg/day로 14일간 경구투여한 군과 투여하지 않은 대조군으로 나누어 12개월간 혈청 HBsAg과 HBeAg을 추적 검사한 결과 두군 모두에서 HBsAg과 HBeAg의 감소를 볼 수 없었으므로 ribavirin의 소아만성B형간염에 대한 치료효과는 없는것으로 보여진다. 또한 ribavirin 치료에 따른 특별한 부작용도 볼 수 없었다.

To study the therapeutic effect of ribavirin, a broad spectrum antiviral agent, for chronic hepatitis B in pediatric patients, 24 patients who were diagnosed as chronic hepatitis B (elevated SGOT and SGPT and positive HBsAg and HBeAg for more than 6 months) at the pediatric department of Yeungnam University Hospital from Mar. 1, 1985 to Sep. 30, 1986 were randomly divided into two groups. Ribavirin was administered to 11 patients in dose of 15mg/kg/day and 13 patients were control group and both groups were followed for 12 months. Serum HBsAg and HBeAg were measured with RIA(Ausria-1I and Abbott-HBe, respectively) and compared in PIN ratio (counts per minute of patient's sample/counts per minute of normal serum). There were no statistically significant reductions in PIN ratios of HBsAg and HBeAg in both groups between prior to the therapy and 12 months follow-up period. It seems that ribavirin does not have the therapeutic effect on chronic hepatis B in children. Also, there were no noticeable side effects from ribavirin therapy.